Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001123292-25-000148·GILEAD SCIENCES, INC.
Schedule 13G ownership disclosure
KALARIS THERAPEUTICS INC
Common Stock, $0.0001 per value · CUSIP: 482929106
Event date: 2025-03-18
- Filing-level shares
- 723,273
- Percent of class
- 3.9%
- GILEAD SCIENCES, INC.
Shares: 723,273 · Class: 3.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001123292-25-000148
- Form type
- SCHEDULE 13G/A
- Filer
- GILEAD SCIENCES, INC.
- CIK
- CIK 882095
- Filed
- Mar 20, 2025
- Reporting period
- Mar 18, 2025
- Description
- Schedule 13G beneficial ownership